(ANIK) Anika Therapeutics - Ratings and Ratios
Pain Management, Joint Restoration, Joint Preservation, Orthopedic Implants
ANIK EPS (Earnings per Share)
ANIK Revenue
Description: ANIK Anika Therapeutics
Anika Therapeutics Inc. is a joint preservation company that develops, manufactures, and commercializes innovative products based on its proprietary hyaluronic acid (HA) technology platform, targeting osteoarthritis pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions. The companys product portfolio includes injectable viscosupplements like Monovisc and Orthovisc, as well as Cingal, a single-injection OA pain management product. Anikas joint preservation and restoration product family encompasses orthopedic regenerative solutions, sports medicine solutions, and preserving joint solutions, including partial joint replacement and joint resurfacing implants.
The companys diverse product offerings also extend to non-orthopedic applications, including veterinary products like Hyvisc, anti-adhesion barriers like Hyalobarrier, and treatments for burns, ulcers, and ear, nose, and throat disorders. With a strong foundation in HA technology, Anika Therapeutics has established itself as a leader in the orthopedic and regenerative medicine markets. The companys commitment to innovation and early intervention orthopedic care has enabled it to expand its global presence, with products available in the United States, Europe, and internationally.
Analyzing the provided technical data, ANIKs current price is 12.41, with its 20-day SMA at 13.95, 50-day SMA at 14.79, and 200-day SMA at 19.26, indicating a downtrend. The ATR of 0.85 represents a 6.84% volatility. Given the current trend and the fact that the stock is trading near its 52-week low of 11.64, a potential support level, it is likely that the stock will experience a bounce or consolidation in the near term. However, the long-term trend remains bearish, and a break below the 52-week low could lead to further declines.
Combining the technical analysis with fundamental data, ANIKs market capitalization stands at 166.93M USD, with a forward P/E ratio of 46.73, indicating high growth expectations. However, the companys RoE of -29.96 suggests significant losses. To forecast the stocks performance, we can consider the potential impact of new product launches, such as Cingal, and the companys expanding presence in the regenerative medicine market. If Anika Therapeutics can demonstrate improved profitability and growth, the stock may experience a re-rating, potentially driving the price towards the 20-day SMA of 13.95. However, failure to address the current losses and improve profitability could lead to further declines, potentially testing the 52-week low.
Additional Sources for ANIK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ANIK Stock Overview
Market Cap in USD | 161m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1993-04-29 |
ANIK Stock Ratings
Growth Rating | -85.3 |
Fundamental | -44.3 |
Dividend Rating | 0.0 |
Rel. Strength | -53.1 |
Analysts | 4.67 of 5 |
Fair Price Momentum | 7.14 USD |
Fair Price DCF | - |
ANIK Dividends
Currently no dividends paidANIK Growth Ratios
Growth Correlation 3m | -85.5% |
Growth Correlation 12m | -94% |
Growth Correlation 5y | -80% |
CAGR 5y | -20.87% |
CAGR/Max DD 5y | -0.27 |
Sharpe Ratio 12m | -0.69 |
Alpha | -68.48 |
Beta | 0.773 |
Volatility | 52.88% |
Current Volume | 144k |
Average Volume 20d | 55.3k |
Stop Loss | 10.4 (-5.3%) |
As of July 09, 2025, the stock is trading at USD 10.98 with a total of 144,047 shares traded.
Over the past week, the price has changed by +4.27%, over one month by -4.69%, over three months by -16.44% and over the past year by -57.39%.
Probably not. Based on ValueRay´s Fundamental Analyses, Anika Therapeutics (NASDAQ:ANIK) is currently (July 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.33 and therefor a somewhat negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANIK is around 7.14 USD . This means that ANIK is currently overvalued and has a potential downside of -34.97%.
Anika Therapeutics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANIK.
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ANIK Anika Therapeutics will be worth about 8.5 in July 2026. The stock is currently trading at 10.98. This means that the stock has a potential downside of -22.5%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 21.3 | 94.3% |
Analysts Target Price | 21.3 | 94.3% |
ValueRay Target Price | 8.5 | -22.5% |